Targeting the Prostacyclin
Pathway with Selexipag in
Patients with Pulmonary Arterial
Hypertension Receiving Double
Combination Therapy: Insights
from the Randomized Controlled
GRIPHON Study
Coghlan JG et al. Am J Cardiovasc
Drugs 2018; 18(1): 37–47.
PAH – ABSTRACT DES MONATS
Aktuell. Kompakt. Informativ.
Klicken Sie hier
Patienten­material
Risiko­stratifi­zierung
Gesundheits­ökonomie